0 560

Cited 13 times in

The Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer

 Hak Woo Lee  ;  Hak Min Lee  ;  Sung-Eun Choi  ;  Hanna Yoo  ;  Sung Gwe Ahn  ;  Min Kyung Lee  ;  Joon Jeong  ;  Woo-Hee Jung 
 JOURNAL OF NUCLEAR MEDICINE, Vol.57(8) : 1183-1188, 2016 
Journal Title
Issue Date
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents ; Breast Neoplasms/diagnostic imaging* ; Breast Neoplasms/drug therapy* ; Breast Neoplasms/mortality ; Chemotherapy, Adjuvant ; Drug Monitoring/methods ; Drug Monitoring/statistics & numerical data* ; Early Detection of Cancer/statistics & numerical data ; Female ; Fluorodeoxyglucose F18* ; Humans ; Image Interpretation, Computer-Assisted/methods ; Middle Aged ; Neoplasm Invasiveness ; Neoplasm Recurrence, Local/diagnostic imaging ; Neoplasm Recurrence, Local/mortality ; Neoplasm Recurrence, Local/prevention & control* ; Neoplasm, Residual ; Positron-Emission Tomography/methods ; Positron-Emission Tomography/statistics & numerical data* ; Prevalence ; Prognosis ; Radiopharmaceuticals ; Reproducibility of Results ; Republic of Korea/epidemiology ; Retrospective Studies ; Risk Factors ; Sensitivity and Specificity ; Survival Rate ; Treatment Outcome
18F-FDG PET ; breast cancer ; neoadjuvant chemotherapy ; standardized uptake value
SUV, which is an indicator of the degree of glucose uptake in (18)F-FDG PET, can be applied as a prognostic factor in various malignant tumors. We investigated the prognostic impact of early changes in (18)F-FDG PET uptake in patients with locally advanced breast cancer who received neoadjuvant chemotherapy.

METHODS: We retrospectively identified 87 patients who were treated with neoadjuvant chemotherapy followed by surgery for locally advanced breast cancer. All patients underwent (18)F-FDG PET at baseline and after 3 cycles of neoadjuvant chemotherapy, and the SUVmax of the primary tumor was assessed in each scan. Pathologic slides were retrospectively reviewed, and the residual cancer burden (RCB) index was calculated to estimate pathologic response. RCB-0 indicates no residual disease; patients with residual disease were categorized as RCB-1 (minimal residual disease), RCB-2 (moderate residual disease), or RCB-3 (extensive residual disease).

RESULTS: There was a negative correlation between reduction in SUVmax and RCB index (r = -0.408; P < 0.001). On multivariate analysis, ΔSUVmax was a significant independent prognostic factor for recurrence-free and overall survival, and the respective adjusted hazard ratios were 0.97 (95% confidence interval, 0.95-0.99; P = 0.001) and 0.97 (95% confidence interval, 0.95-0.99; P = 0.015). When patients were categorized into groups according to pathologic response (RCB index ≤ 1 vs. ≥ 2) and metabolic response (ΔSUVmax ≤ 66.4% vs. > 66.4%), metabolic responders had significantly better recurrence-free and overall survival than metabolic nonresponders among poor-pathologic-response patients. In contrast, among metabolic responders, there was no survival difference according to pathologic response.

CONCLUSION: The early change in (18)F-FDG PET SUVmax after third-cycle neoadjuvant chemotherapy is an independent and good prognostic marker beyond pathologic response in patients with locally advanced breast cancer. We suggest that in these patients, the use of ΔSUVmax should be considered not only for the assessment of tumor response but for the prediction of posttreatment outcome.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Ahn, Sung Gwe(안성귀) ORCID logo https://orcid.org/0000-0002-8778-9686
Lee, Hak Woo(이학우)
Jung, Woo Hee(정우희)
Jeong, Joon(정준) ORCID logo https://orcid.org/0000-0003-0397-0005
Choi, Sung Eun(최성은) ORCID logo https://orcid.org/0000-0002-6955-658X
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.